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NDEL1-PDGFRB fusion gene in a myeloid malignancy with
eosinophilia associated with resistance to tyrosine kinase
inhibitors
Leukemia (2017) 31, 237–240; doi:10.1038/leu.2016.250
We have identiﬁed a novel fusion gene NDEL1-PDGFRB in an
18-month-old child with a myeloid neoplasm and eosinophilia.1,2
In contrast to earlier data on fusion genes involving PDGRFB in
myeloid malignancies, which were generally responsive to
treatment with imatinib,3 the patient presented became refractory
to both imatinib and nilotinib. Sequencing of a pertinent gene
panel including NRAS, KRAS, NF1, PTPN11, CBL, FLT3, c-KIT, PDGFRA,
CSF1R, CSF3R, SF3B1, SRSF2, ZRSR2, SH2B3, RUNX1, EZH2, ASXL1,
SETBP1, DNMT3A, TET2 and PTEN at the time of diagnosis and both
relapses revealed no mutations. However, sequence analysis of
the entire tyrosine kinase domain (TKD) of PDGFRB revealed the
D850E mutation in the activation loop (A-loop). This mutation was
identiﬁed in the peripheral blood and bone marrow specimens
from both relapses in virtually all cells belonging to the leukemic
clone, but was undetectable in the diagnostic peripheral blood or
bone marrow. In order to elucidate the structural effects mediated
by the D850E mutation in the PDGFRβ TKD, we have generated
structure models of the kinase domain both in active (DFG-in) and
inactive (DFG-out) conformations, which interact preferentially
with type-I and type-II tyrosine kinase inhibitors (TKIs), respectively
(Figure 1).4 As the structure of PDGFRβ TKD at the level of atomic
resolution is not yet available, we have modelled the kinase
domain on the basis of crystallographic structures of closely
related homologous proteins including c-KIT, CSF1R and VEGFR2.
All structural models indicated that the observed type-II TKI
resistance of cells expressing the D850E mutation in NDEL1-
PDGFRβ was conceivably related to stabilization of the A-loop in
the active conformation. In this conformation, the DFG triad
serving as a hypomochlion for the A-loop adopts the so-called
DFG-in position.5 The modelled structure of the inactive DFG-out
conformation (Figure 1a; orange) revealed the typical auto-
inhibitory interaction between D850 and the amino acid at the
+3 position, R853, which is commonly observed in inactive TKDs of
other receptor tyrosine kinases (RTKs) from the PDGFR family, and
is believed to stabilize the A-loop in the inactive conformation
(Figure 1b).6–8 However, modelling of the mutant PDGFRβ TKD in
the inactive conformation could not explain the resistance to type-
II TKIs and the enhanced kinase activity addressed below, because
the negatively charged E850 is also able to form a salt bridge with
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the positively charged side chain of R853. By contrast, the DFG-in
model suggested the occurrence of two intriguing amino acid
interactions upon transition of the A-loop from inactive to the
active state (Figure 1a; green). One interaction implicated the
negatively charged D850 and the positively charged, conserved
H657 in the αC-helix (Figure 1c), which is expected to stabilize the
A-loop in the active conformation.9 This interaction can be
further enhanced by the D850E mutation, because the longer
side chain of glutamate in comparison with aspartate brings
the negatively charged carboxylic group 1.1 Å closer to the
positively charged histidine. This increases the stability of
the A-loop in the active conformation (Figure 1d), because the
forces of electrostatic interaction between opposite charges
increase with the second power of decreasing distance, and
become largely ineffective at distances exceeding 4.5 Å.10 The
structural model also suggested that the mutation H657K would
have an effect similar to the mutation D850E in terms of
stabilizing the active conformation (Figure 1e). The other
interaction involved R853 and E946 in the C-lobe of the TKD
(Figure 1f). The +3 position to D850 is one of the least conserved
positions in the A-loop of RTKs from the PDGFR family
(Figure 1h), and the arginine at this position in PDGFRβ (R853)
has the longest side chain among all members. The DFG-in
model suggested that the positively charged side chain of R853
can reach a distance of ~ 2.7 Å to the negatively charged
carboxyl group of E946, which may facilitate electrostatic
bonds and provide additional stabilization of the DFG-in
conformation of the PDGFRβ TKD. The structural model
therefore suggested resistance of NDEL1-PDGFRB with the
D850E mutation to type-II TKIs, which can only bind to the
inactive conformation of the PDGFRβ TKD, but indicated
sensitivity to type-I TKIs binding to the active conformation.
To address the predictions provided by the protein model, we
have introduced several mutations affecting the aforemen-
tioned interactions, and tested the sensitivity of generated
constructs against a panel of TKIs.
To assess the oncogenic potential of the newly identiﬁed fusion
gene, the murine cell line Ba/F3 was stably transduced with wild-
type or mutant NDEL1-PDGFRB constructs by employing a
transposon-based system.11 In addition to the D850E mutation
observed in the patient, a construct carrying the H657K mutation
was generated. This mutation was expected to strengthen the
electrostatic interaction between D850 and the αC-helix, thus
stabilizing the DFG-in conformation of the PDGFRβ TKD
(Figure 1e). In order to determine the inﬂuence of R853 in the
PDGRFβ TKD on the kinase activity and TKI-sensitivity, constructs
carrying R853H were generated (Figure 1g). Ba/F3 cells expressing
the H657K and D850E mutant versions of NDEL1-PDGFRB
displayed an elevated in vitro kinase activity, whereas constructs
with the R853H mutation showed a kinase activity identical to cells
carrying wild-type NDEL1-PDGFRB. The phosphorylation level of
PDGFRβ and one of its downstream targets, Erk, which is activated
via the Ras-pathway,12 was higher in Ba/F3-NDEL1-PDGFRB cells
carrying the H657K or D850E mutations in comparison with
wildtype or R853H-carrying fusion gene constructs (Figure 2b).
Figure 1. Protein models of the PDGFRβ TKD structure. (a) The modelled DFG-out (orange) and DFG-in (green) conformations of PDGFRβ TKD
are displayed. The zoom-in windows show the relevant stabilizing electrostatic interactions with the corresponding distances between
charges: (b) D850-R853 in the DFG-out model; (c) H657-D850, (d) H657-E850, (e) K657-D850, (f) R853-E946 and (g) H853-E946 in the DFG-in
model. Oxygen atoms carrying negative charge are marked in red, nitrogen atoms carrying positive charge in blue. The gray arrow in the
center indicates rotation of the A-loop upon transition from inactive to active state. (h) Sequence alignment of RTKs from the PDGFR family
depicting the region covering αC-helices and A-loops of PDGFRα, PDGFRβ, FLT3, CSF-1 R and c-Kit.
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The in vitro responsiveness of Ba/F3-NDEL1-PDGFRB cells to
different TKIs of type-I (dasatinib, midostaurin and pacritinib) and
type-II (imatinib, nilotinib and sorafenib) was determined by MTT
assays. Cells expressing wild-type NDEL1-PDGFRB were sensitive to
all TKIs tested (Figure 2a). By contrast, proliferation of Ba/F3 cells
carrying the D850E mutation in the NDEL1-PDGFRB gene could
only be inhibited by the indicated type-I TKIs at sub-micromolar
concentrations (Figure 2a). The observation of TKI resistance
apparently induced by the D850E mutation in the kinase domain
of PDGFRβ was in contrast to the same amino acid exchange at
the corresponding site in PDGFRα (D842E).13 This ﬁnding raised
questions regarding important structural differences between the
two highly homologous RTKs. While PDGFRβ displays an arginine
in the +3 position to the mutation site (R853), PDGFRα has the
much shorter and less basic histidine in the corresponding
position (H845) (Figure 1h). It appeared conceivable, therefore,
that the interaction between the side chains of R853 and E946 in
the mutant PDGFRβ TKD could stabilize the active conformation in
the presence of H657K or D850E mutations, thus mediating
resistance to type-II TKIs. To address this notion, the mutation
R853H was introduced into NDEL1-PDGFRB constructs, thus
mimicking the sequence of the A-loop in the PDGFRα TKD
(Figure 1h). In line with the properties of the D842E mutation in
the FIP1L1-PDGFRα fusion, this change restored the TKI type-II
sensitivity of cells carrying one of the activating mutations, H657K
or D850E, in NDEL1-PDGFRβ (Figure 2).
The position of the newly identiﬁed mutation D850E in PDGFRβ
corresponds to well-known mutation sites within the activation
loop of other members of the PDGFR-RTK family including c-KIT
(D816),14 PDGFRα (D842)13,15 and FLT3 (D835)5 (Figure 1h).
Mutations converting the aspartate residue at the indicated
positions into a bulky hydrophobic residue were shown to
mediate resistance to type-II TKIs.5,15,16 Structural studies
revealed that the interaction of the residues D816 in c-KIT and
D835 in FLT3 with the residue at the +3 position (N819 in
c-KIT and S838 in FLT3) may maintain the auto-inhibitory
inactive conformation of the A-loop.6 Notably, clinically relevant
activating mutations D816V in c-KIT and D835V/Y in FLT3
converting the aspartate into a residue with bulky hydrophobic
or aromatic side chain would disrupt the hydrophilic inter-
actions with the corresponding residue at +3 position. However,
a conversion of aspartate to glutamate, representing an
exchange between two hydrophilic and negatively charged
amino acids at this position, has never been associated with
resistance to type-II TKIs.5,13,16 In marked contrast to the clinical
and in vitro data presented, the identical mutation at the
corresponding site in the TKD of PDGFRα (D842E) in the fusion
gene FIP1L1-PDGFRA associated with chronic eosinophilic
leukemia did not cause any signiﬁcant increase in IC50 values
of the type-II TKIs imatinib, nilotinib and sorafenib13 (Figure 2a).
Similarly, the same mutation at the corresponding site of FLT3
associated with acute myeloid leukemia, D835E, did not
signiﬁcantly increase the IC50 to the type-II TKIs sunitinib and
sorafenib5,16 but enhanced the kinase activity of FLT3, and
mediated growth factor-independent proliferation of the murine
hematopoietic cell line Ba/F3.17 However, although these
Figure 2. TKI responsiveness of wild-type and mutant NDEL1-PDGFRB genes. (a) Displayed are IC50 values of different TKIs against Ba/F3 cells
expressing wild-type (wt) or mutant NDEL1-PDGFRβ fusion proteins. The corresponding IC50 values for Ba/F3 expressing FIP1L1-PDGFRα wt
and D842E are given for comparison. (b) Western blot analysis of Ba/F3 cells transduced with wild-type or mutant (R= R853H, H=H657K,
HR=H657K/R853H, D=D850E and DR=D850E/R853H) NDEL1-PDGFRB genes. The phosphorylation levels of NDEL1-PDGFRβ at Y751 and Y857,
and Erk are displayed. Shown are also the total expression levels of NDEL1-PDGFRβ, Erk and the control gene Gapdh upon mock treatment for
4 h with DMSO (indicated by ‘− ‘) or with 100 nM nilotinib (indicated by ‘+’).
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analogies are in line with the enhanced kinase activity of the
D850E PDGFRβ mutant, they do not explain the observed
resistance to type-II TKIs. In this regard, it is important to
examine the protein model in the context of intramolecular
interactions speciﬁc for PDGFRβ TKD. Protein modelling of the
PDGFRβ TKD suggested that the residue in +3 position, R853,
which differs from corresponding sites in all other RTKs of the
PDGFR family, mediates a critical amino acid interaction
stabilizing the A-loop in the active conformation, thereby
preventing the interaction of type-II TKIs with their target sites
in the kinase domain. This notion was conﬁrmed by mutating
R853 to histidine, the amino acid present at the corresponding site
in PDGFRα, which decreased the kinase activity and restored
sensitivity of NDEL1-PDGFRβ with D850E or H657K to type-II TKIs.
The ﬁndings not only conﬁrm the important role of R853 in
establishing the resistant phenotype of the mutant NDEL1-
PDGFRB, but also underline the potential of protein modelling
for prediction of sensitivity and resistance to TKI treatment. The
data presented provide new insights into speciﬁc amino acid
interactions in mutant RTKs that are of clinical relevance for
improved selection of appropriate TKI treatment.
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